About us
Services & Solutions
Chemistry Drug Metabolism and Pharmacokinetics (DMPK) Discovery Biology Oncology Pharmacology Biologics
Medicinal Chemistry Parallel Synthesis Peptide Chemistry Computational Chemistry Synthetic Chemistry Analytical Chemistry Scale Up Chemistry
In Vivo PK and TK In Vitro ADME Bioanalytical Service Toxicity In Rodents, Dogs and Monkeys Large Molecule Development and Bioanalysis
Fragment Based Drug Discovery (FBDD) Biochemical Assays Cellular Assays Protein Science Assay Technologies Biophysics SPR Safety Pharmacology Screening Services Key Instruments
PDX CDX Orthotopic Models Syngeneic Models Humanized Mouse Models CAR-T and CAR-NK Mouse Models In Vitro Assays
Immunology Inflammation Metabolic MASH Mouse Models Respiratory Neuroscience
Systematic Antibody Discovery Service
Process R&D Scale Up Synthesis DS Manufacturing
Flow Chemistry Sugar Chemistry Peptide Chemistry Preparative Purification Capacity Process Safety Assessment
Synthetic and Scale Up Chemistry
Kilo and Pilot Scale Production RSM and Intermediates Manufacturing QA EHS
Preformulation Formulation, Analytical, and Process Development Drug Product Manufacturing
Hot Melt Extrusion (HME) Spray Dried Dispersion (SDD) Amorphous Solid Dispersions (ASD) Bioavailability Enhancement Modified Release
Clinical Manufacturing Commercial Manufacturing
Platforms
News & Resources
Careers
Contact us
×

FRAGMENT-BASED DRUG
DISCOVERY (FBDD)

Find your Next Hit with the BioDuro-Sundia Fragment Screening Platform

Home Services & Solutions Discovery Discovery Biology Fragment Based Drug Discovery (FBDD)

Fragment Based Drug Discovery (FBDD)

FBDD Services Overview
BioDuro-Sundia maintains a diverse fragment library of 2,000-3,000 internally synthesized fragments with important pharmacophores to enable Fragment Based Drug Discovery (FBDD) by screening against a target.
Combined with our fragment screening technology and Biocore 8K surface plasmon resonance (SPR) system, we quickly identify fragments which bind to the target.
Part of a powerful integrated CRDMO, our FBDD capabilities accelerate hit identification, hit-to-lead optimization, and lead optimization activities for clients’ drug discovery programs. Once a fragment with affinity is found, it's chemically modified or combined with other fragments to improve its properties and create a more potent and selective drug candidate.
Click here to download the PDF version of our FBDD Services Flyer.
Fragment Library
Our fragment library contains 2,000-3,000 fragments to ensure diversity, pharmacophoric content, and novelty. ~1,000 fragments are selected from commercially available libraries, such as Life Chemicals, allowing our services to focus on screening and optimization. The other ~1,000 fragments are less conventional structures not commonly found in existing drug molecules.
We include novel scaffolds (e.g. natural products and traditional Chinese medicine) and exclude functional groups with known structural alerts (i.e. reactive, toxic, aggregators, PAINS compounds).
Our collection of both conventional and non-conventional fragments increases the likelihood to identify potent and selective compounds to produce unique and differentiated drug candidates.
Fragment Library Highlights:

2,000 fragments: 50% internally synthesized

Ro3 compliant drug lead-like fragments

240 NP-like fragments

Free from known structural alerts

Fragment Library Selection Criteria:

100 ≤ MW < 300

0 < ClogP ≤ 2.75

Purity ≥ 95% (metal ion free)

Aqueous solubility ≥ 1 mM; DMSO solubility ≥ 100 mM (room temperature)

HBD ≤ 3

HBA ≤ 6

Nrot ≤ 4

20 ≤ TPSA ≤ 90

1.jpg
Fragment Screening with SPR
Our in-house Biacore 8K surface plasmon resonance (SPR) system enables quick, efficient and high-throughput fragment screening and characterization. We provide fragment library screening services as well as and follow-up studies with affinity and kinetics characterization by SPR.
Fragment Screening Highlights:

Robust with wide dynamic range (Kd: nM – mM)

Quantitative binding info: kon, koff, Kd

Binding stoichiometry

Very low protein consumption

High-throughput (Biacore 8K)

2.jpg
Cytiva Biacore 8k: High Throughput and High Sensitivity SPR System

Parallel setup, 8 channels, 2 cells/channel

Ideal for fragment based screening (FBS) and rapid follow-ups with dose-response confirmation of fragment hits

oIdeal for supporting fragment optimization and evolution with Kd and binding kinetics

3.jpg
Chemistry
Medicinal Chemistry Parallel Synthesis Peptide Chemistry Computational Chemistry Synthetic Chemistry Analytical Chemistry Scale Up Chemistry
Drug Metabolism and Pharmacokinetics (DMPK)
In Vivo PK and TK In Vitro ADME Bioanalytical Service Toxicity In Rodents, Dogs and Monkeys Large Molecule Development and Bioanalysis
Discovery Biology
Fragment Based Drug Discovery (FBDD) Biochemical Assays Cellular Assays Protein Science Assay Technologies Biophysics SPR Safety Pharmacology Screening Services Key Instruments
Oncology
PDX CDX Orthotopic Models Syngeneic Models Humanized Mouse Models CAR-T and CAR-NK Mouse Models In Vitro Assays
Pharmacology
Immunology Inflammation Metabolic MASH Mouse Models Respiratory Neuroscience
Biologics
Systematic Antibody Discovery Service
Subscribe to BioDuro-Sundia
Receive our newsletter and information on upcoming events
Your trusted partner from drug discovery and
development to commercialization

Home

About us

Services & Solutions

Platforms

News & Resources

Careers

Contact us

Explore

Discovery

Drug Substance

Drug Product

© 2023 BioDuro-Sundia. All rights reserved
Terms of Use Privacy Policy
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all